Second Annual Conference of
The International Society for the Study of Drug Policy

Scientific Programme

Thursday April 3, 2008

9.00  Opening Session
Fátima Trigueiros, IDT, I.P.
Roland Simon, EMCDDA
Peter Reuter, ISSDP President
Henri Bergeron, Conference Chair

9:30  Plenary Session/Auditorium
Chair: Peter Reuter (University of Maryland, USA)

Drug Policy in World Historical Perspective: The Five Stages of Regulation
David Courtwright (University of North Florida, USA)

10. 15 Parallel sessions A&B

1 a) Policy Evaluation I
Chair: Henri Bergeron (CSO-CNRS – Sciences Po Paris, France)

The development of an Australian drug policy index
Speaker: Alison Ritter (Drug Policy Modeling Program, University of New South Wales, Australia)

Cocaine and the Caribbean: evaluating UK and Dutch counter-drugs policies
Speaker: Martin Elvins (University of Dundee, U.K.)

Regulating khat: Dilemmas and opportunities
Speaker: Axel Klein (University of Kent, U.K.)

Discussant: Casimiro Balsa (Faculdade de Ciências Sociais e Humanas, Universidade Nova de Lisboa, Portugal)

1 b) Policy Evaluation II
Chair: Maria Moreira (EMCDDA, Portugal)

Evaluating Danish cannabis policy change
Speaker: Kim Møller (Center for Alcohol and Drug Research, Denmark)

The cannabis classification debate in the UK: full of sound and fury, signifying nothing.
Speaker: Charlie Lloyd (Joseph Rowntree Foundation, U.K.)

The baby, the bathwater and the legacy of normalization: understanding young people’s drug use
Fiona Measham (Lancaster University, UK)

Discussant: Fernando Mendes (IDT, I.P., Portugal)

11.45  Coffee – break
12:00  Parallel sessions

2 a) Modeling drug treatment
Chair: Julian Vicente (EMCDDA, Portugal)

The role of medicine assisted drug treatment within Nordic drug and health policy - a discussion
Speakers: Pia Rosenqvist (Nordic Council on Alcohol and Drugs, Finland) and Astrid Skretting (SIRUS, Norway)

The dynamics of marijuana treatment
Speaker: Beau Kilmer (Drug Policy Research Center, RAND, USA)

Is it in medical centers’ self-interest to provide drug dependence treatment? : a cost-consequence analysis in a national health care system
Speaker: Keith Humphreys (Stanford University, USA)

Discussant: Ambros Uchtenhagen (Research Institute for Public Health and Addiction, Switzerland)

2b) Managing drug-involved offenders
Chair: Miguel Vasconcelos (IDT, I.P., Portugal)

Drug Testing and Sanctions in Hawaii: Preliminary Results from Project HOPE
Speaker: Mark Kleiman (UCLA, USA)

The Beginning of HOPE
Steven Alm (1st Judicial Circuit, Hawaii, USA)

Behavioral Economics and Parole Supervision
Angela Hawken (Pepperdine University, USA) [paper to be presented by Mark Kleiman]

Discussant: Nicola Singleton (UK Drug Policy Commission, UK)

1:30 pm  Lunch

2.30 pm  Plenary Session
Chair: Michael Farrell (National Addiction Center, UK)

The adverse health effects of cannabis and their implications for policy
Wayne Hall (University of Queensland, Australia)

3.15 pm  Parallel sessions

3a) Governance and policy formation
Chair: Laurent Laniel (EMCDDA, Portugal)

An ecological system view of United States illicit drugs policy and the role of public health
Yvonne M. Terry-McElrath (University of Michigan, USA)

Malaysian illicit drug policy: top down multi agency governance or bottom up multi level governance
Vicknasingam Balasingam Kasinather (Centre For Drug Research, University Sains Malaysia, Malaysia)

Harm-reduction measures, police activity and incidence of heroin use: the Zurich experience
Carlos Nordt (Psychiatric University Hospital, Zurich, Switzerland)

Discussant: Suzanne McGregor (London School of Hygiene and Tropical Medicine, UK)
3b) **Formal models, policy and inertia**

**Chair:** Lucas Wiessing (EMCDDA, Portugal)

**Optimal use and harm reduction in drug epidemics**  
*Dagmar Wallner and Gernot Tragler* (Technical University of Vienna, Austria)

**A system dynamic model of Australian opioid pharmacotherapy maintenance treatment**  
*Jenny Chalmers* (Drug Policy Modeling Program, University of New South Wales, Australia)

**Understanding inertia: inherent limitations on evaluating “upstream” drug control interventions**  
*Jonathan P. Caulkins and Imrgard Zeiler* (Carnegie-Mellon University, USA)

**Discussant:** Peter Reuter (University of Maryland, USA)

4.45 pm  **Coffee-break**

5.00 pm  **Annual meeting of the ISSDP**

6.00 pm  **End of the Day**

7.00 pm  **Reception by the Portuguese hosts**  
“Museu da Cidade” – The City Museum

---

Friday April 4, 2008

**9.00  Plenary Session**

**Chair:** Sandeep Chawla (UNODC, Austria)

**From fundamentalism to technocracy – learning from Swiss policy failures in the fight against drug abuse.**  
*Sandro Cattacin* (University of Geneva, Switzerland)

**9.45  Parallel sessions A&B**

**4a) Drug market dynamics I**

**Chair:** Kevin Sabet (NDRI, USA)

**Price variation in the UK market for cocaine and heroin**  
*Kevin Marsh* (Matrix Research and Consulting, UK)

**The “flexible” response of cannabis markets to enforcement/interdiction policy: An international review of market transformations and elasticities**  
*Bruce D. Johnson* (NDRI, USA)

**Modelling cocaine and heroin market in the era of globalization and drug reduction policies**  
*Cláudia Costa Storti* (EMCDDA, Portugal)

**Discussant:** Benedikt Fischer (University of Victoria, Canada)
4b) Drug market dynamics II

Chair: Chloé Carpentier (EMCDDA, Portugal)

A few buds for a few bucks? Youth involvement in the marijuana cultivation industry
Martin Bouchard (Simon Fraser University, Canada)

High-dose buprenorphine: A shock on the supply-side market of the heroin in France
Christian Ben Lakhdar (OFDT, France)

A search-theoretic model of the retail market for illicit drugs
Rosalie Liccardo Pacula (Drug Policy Research Center, RAND, USA)

Discussant: Mark Kleiman (UCLA, USA)

11.15 Coffee

11.30 Parallel sessions A&B

5a) Costs and Expenditures
Chair: Fátima Trigueiros (IDT, I.P., Portugal)

Public expenditures on drug policy
Jiri Vopravi (National Statistical Office, The Czech Republic)

Proposal of a new standardized data collection form to estimate drug-related public expenditures in the European Union
Luis Prieto (EMCDDA, Portugal)

An alternative framework for measuring the economic cost of drug abuse
Rosalie Pacula (Drug Policy Research Center, RAND, USA)

Discussant: Harold Pollack (University of Chicago, USA)

5b) Testing and Incarceration
Chair: Jorge Negreiros (Faculdade de Psicologia e Ciências da Educação, Universidade do Porto, Portugal)

Drug testing in Schools and Workplaces: Policy implications and considerations of punitive deterrence and/or prevention measures
Ann M. Roche (National Center for Education and Training, Australia)

Drug testing in schools -- evaluating a high school's drug testing program: Implications for future school drug testing policies
Howard Taras (University of California, San Diego, USA)

Alternatives to what? The effects of alternatives to prison for drug-related offenders
Alex Stevens (University of Kent, UK)

Drugs and prisons in Portugal: inmates and directors, agreements and disagreements
Anaíla Cardoso Torres (Instituto Superior de Ciencias do Trabalho e da Empresa, Portugal)

Discussant: Brendan Hughes (EMCDDA, Portugal)

1.30 pm Lunch
2.30 pm **Plenary Session**

**Chair:** Margaret Hamilton (Australian National Council on Drugs)

**Maintaining Addicts on Heroin: Making Sense out of Apparent Nonsense**
*John Strang (National Addiction Center, UK)*

3.15 pm **Parallel sessions**

6 a) **Drug problem – use patterns and consequences**

**Chair:** Frank Zobel (EMCDDA, Portugal)

**Youth, contemporary drug policy, social control, the dance scene and social control**
*Geoffrey Hunt (Institute for Scientific Analysis, USA)*

**Using microsimulation modeling to capture heterogeneity in marijuana use**
*Susan M. Paddock (Drug Policy Research Center, RAND, USA)*

**Biography of an epidemic: The outbreak (and decline) of fentanyl overdose deaths in Chicago**
*Harold A. Pollack, Greg Scott and Sandra D. Thomas (University of Chicago, USA)*

**Discussant:** Jean-Michel Costes (OFDT, France)

6b) **Policy change: analysis and models**

**Chair:** Henri Bergeron (CSO-CNRS – Sciences Po Paris, France)

**Complementary or contradictory drug policies**
*Michael Jourdan (Center for Alcohol and Drug Research, Denmark)*

**Risk, Security and the ‘Criminalization’ of British Drug Policy**
*Robert Ralphs and Lisa Williams (University of Manchester, UK)*

**The Dutch drug policy: an overview and an exploratory evaluation**
*M.M.J. van Ooyen-Houben (Ministry of Justice, Netherlands)*

**Variations in Effective Illegality and Their Effects Upon The World Opiate Market**
*Letizia Paoli, (Katholik University of Leuven, Belgium)*

**Discussant:** Robin Room (Turning Point, Australia)

4.45 pm **Coffee break**

5.00 pm **Final address**